Impact of cytokine inhibitor therapy on the prevalence, seroconversion rate and longevity of the humoral immune response against SARS ‐CoV‐2 in an unvaccinated cohort

ConclusionsIMID patients treated with bDMARDs have a lower prevalence of SARS-CoV-2 antibodies, seroconvert less frequently after SARS-CoV-2 infection and may exhibit a reduced longevity of their humoral immune response.This article is protected by copyright. All rights reserved.

Source: Arthritis and Rheumatology - December 24, 2021 Category: Rheumatology Authors: David Simon, Koray Tascilar, Arnd Kleyer, Filippo Fagni, Gerhard Kr önke, Christine Meder, Peter Dietrich, Till Orlemann, Thorsten Kliem, Johanna Mößner, Anna‐Maria Liphardt, Verena Schönau, Daniela Bohr, Louis Schuster, Fabian Hartman Tags: Brief Report Source Type: research